Literature DB >> 26115944

Audiovestibular disorders as autoimmune reaction in patients with melanoma.

S Barozzi1, D Ginocchio2, M Socci2, D Alpini3, A Cesarani2.   

Abstract

Melanoma is an aggressive form of cancer derived from neuroectodermal melanocytes. Melanocytes are present in the skin and hair follicles, as well as in the eye (iris and choroids), the leptomeninges, the anal canal and the inner ear. In the inner ear melanocytes are found both in the intermediate layer of the stria vascularis of the cochlea and in the dark cells of the vestibular organs. They are believed to play an important role in the production of endolymphatic potentials and in the maintenance of normal volumes of the inner ear fluids. Recently, audiovestibular dysfunctions have been demonstrated in patients treated with immunotherapy for metastatic melanoma and have been related to an autoimmune attack on the normal melanocytes of the inner ear. Melanoma is an immunogenic tumor type frequently associated with spontaneous autoimmune manifestations which seem to be associated with better prognosis. The melanoma-associated antigens are also expressed in normal melanocytes in the skin, eye and ear. We hypothesize that inner ear melanocytes could be a target of an autoimmune process in patients affected by melanoma. The immune system could produce antibodies that cross-react with both the melanoma cells and the labyrinth melanocytes causing an altered homeostasis of endolymphatic liquids and provoking some labyrinthic disorders such as vertigo, hearing loss, aural fullness and tinnitus resembling or influencing Ménière's disease. In this perspective, audiovestibular disorders could be interpreted as an attempt by the individual immune system to develop anti-tumor response. In patients affected by melanoma an autoimmune genesis has already been advocated for ocular symptoms in melanoma-associated retinopathy, where the cross-reaction happens against retinal cells. A possible role of inner ear melanocytes should be considered as a potential cause of audiovestibular disorders. Further research is needed to demonstrate a connection between melanoma and labyrinth dysfunctions such as in melanoma-associated retinopathy.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26115944     DOI: 10.1016/j.mehy.2015.06.009

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  5 in total

1.  Upregulation of the Nr2f1-A830082K12Rik gene pair in murine neural crest cells results in a complex phenotype reminiscent of Waardenburg syndrome type 4.

Authors:  Karl-F Bergeron; Chloé M A Nguyen; Tatiana Cardinal; Baptiste Charrier; David W Silversides; Nicolas Pilon
Journal:  Dis Model Mech       Date:  2016-09-01       Impact factor: 5.758

2.  Introducing MARCo: Histoserological Findings of a Multi-Organic Paraneoplastic Syndrome in Cutaneous Melanoma Patients.

Authors:  Mahdy Ranjbar; Armin Mohi; Claudia Pföhler; Salvatore Grisanti; Martin Rudolf
Journal:  Dermatol Ther (Heidelb)       Date:  2016-09-01

3.  Cochlear Impairment and Autoimmune Ear Disorder in a Patient with Breast Cancer.

Authors:  Alessandra Fioretti; Vittoria Di Rubbo; Giorgia Peri; Elisa Vitti; Sara Cisternino; Theodoros Varakliotis; Alberto Eibenstein
Journal:  Audiol Res       Date:  2017-03-13

4.  Migration and fate of vestibular melanocytes during the development of the human inner ear.

Authors:  Edward S A van Beelen; Wouter H van der Valk; John C M J de Groot; Erik F Hensen; Heiko Locher; Peter Paul G van Benthem
Journal:  Dev Neurobiol       Date:  2020-11-02       Impact factor: 3.964

5.  Nerve-associated Schwann cell precursors contribute extracutaneous melanocytes to the heart, inner ear, supraorbital locations and brain meninges.

Authors:  Marketa Kaucka; Bara Szarowska; Michaela Kavkova; Maria Eleni Kastriti; Polina Kameneva; Inga Schmidt; Lucie Peskova; Alberto Joven Araus; Andras Simon; Jozef Kaiser; Igor Adameyko
Journal:  Cell Mol Life Sci       Date:  2021-07-18       Impact factor: 9.261

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.